eXoZymes files S-1 for offering of common stock and purchase warrants

eXoZymes Inc., which trades on The Nasdaq Capital Market under the symbol "EXOZ," filed a registration statement with the Securities and Exchange Commission on November 6, 2026.¹ The filing covers an unspecified number of shares of common stock and purchase warrants, with each two shares offered together with one accompanying purchase warrant at an assumed combined offering price equal to two times the last reported Nasdaq sale price on a to-be-determined November date.¹ The purchase warrants are exercisable immediately and expire five years from issuance.¹

Newbridge Securities Corporation is listed as sole book-running manager¹ for the offering. The underwriter has a 30-day option to buy additional shares and warrants at the public offering price, less discounts and commissions.¹

On use of proceeds, the company said it intends to use net proceeds from the offering to further develop opportunities tied to its NCT business and products, advance its next-in-line product candidates, fund research and development, and support working capital and general corporate purposes, including capital expenditures.¹ Dollar amounts for net proceeds were left blank in the filing.

The prospectus also flags risk, noting the company might not be able to continue as a going concern, citing a history of losses and its auditor's substantial doubt about its ability to continue as a going concern.¹ Separately, the filing warns that investors in the offering will see immediate, substantial dilution, that the company will likely issue more common stock in the future, and that a large number of shares could be sold following the offering, potentially pressuring the stock price.¹

The company's lead program remains NCT, marketed under the brand name Tyferyn, which has completed discovery and proof of concept and is now in scale-up, GRAS determination, and parallel clinical studies.¹